Literature DB >> 28655784

Inhibition of Megakaryocyte Differentiation by Antibody-Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia.

Hui Zhao1, Sara Gulesserian2, Sathish Kumar Ganesan2, Jimmy Ou2, Karen Morrison2, Zhilan Zeng2, Veronica Robles2, Josh Snyder2, Lisa Do2, Hector Aviña2, Sher Karki2, David R Stover2, Fernando Doñate2.   

Abstract

Thrombocytopenia is a common adverse event in cancer patients treated with antibody-drug conjugates (ADC), including AGS-16C3F, an ADC targeting ENPP3 (ectonucleotide pyrophosphatase/phosphodiesterase-3) and trastuzumab emtansine (T-DM1). This study aims to elucidate the mechanism of action of ADC-induced thrombocytopenia. ENPP3 expression in platelets and megakaryocytes (MK) was investigated and shown to be negative. The direct effect of AGS-16C3F on platelets was evaluated using platelet rich plasma following the expression of platelet activation markers. Effects of AGS-16C3F, T-DM1, and control ADCs on maturing megakaryocytes were evaluated in an in vitro system in which human hematopoietic stem cells (HSC) were differentiated into MKs. AGS-16C3F, like T-DM1, did not affect platelets directly, but inhibited MK differentiation by the activity of Cys-mcMMAF, its active metabolite. FcγRIIA did not appear to play an important role in ADC cytotoxicity to differentiating MKs. AGS-16C3F, cytotoxic to MKs, did not bind to FcγRIIA on MKs. Blocking the interaction of T-DM1 with FcγRIIA did not prevent the inhibition of MK differentiation and IgG1-mcMMAF was not as cytotoxic to MKs despite binding to FcγRIIA. Several lines of evidence suggest that internalization of AGS-16C3F into MKs is mediated by macropinocytosis. Macropinocytosis activity of differentiating HSCs correlated with cell sensitivity to AGS-16C3F. AGS-16C3F was colocalized with a macropinocytosis marker, dextran-Texas Red in differentiating MKs. Ethyl isopropyl amiloride (EIPA), a macropinocytosis inhibitor, blocked internalization of dextran-Texas Red and AGS-16C3F. These data support the notion that inhibition of MK differentiation via macropinocytosis-mediated internalization plays a role in ADC-induced thrombocytopenia. Mol Cancer Ther; 16(9); 1877-86. ©2017 AACRSee related article by Zhao et al., p. 1866. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28655784     DOI: 10.1158/1535-7163.MCT-16-0710

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  12 in total

1.  Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo.

Authors:  Jason J Zoeller; Aleksandr Vagodny; Krishan Taneja; Benjamin Y Tan; Neil O'Brien; Dennis J Slamon; Deepak Sampath; Joel D Leverson; Roderick T Bronson; Deborah A Dillon; Joan S Brugge
Journal:  Mol Cancer Ther       Date:  2019-04-08       Impact factor: 6.261

2.  Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas.

Authors:  John A Thompson; Robert J Motzer; Ana M Molina; Toni K Choueiri; Elisabeth I Heath; Bruce G Redman; Randeep S Sangha; D Scott Ernst; Roberto Pili; Stella K Kim; Leonard Reyno; Aya Wiseman; Fabio Trave; Banmeet Anand; Karen Morrison; Fernando Doñate; Christian K Kollmannsberger
Journal:  Clin Cancer Res       Date:  2018-05-30       Impact factor: 12.531

3.  An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug Conjugates.

Authors:  Summer Y Y Ha; Yasuaki Anami; Chisato M Yamazaki; Wei Xiong; Candice M Haase; Scott D Olson; Jangsoon Lee; Naoto T Ueno; Ningyan Zhang; Zhiqiang An; Kyoji Tsuchikama
Journal:  Mol Cancer Ther       Date:  2022-09-06       Impact factor: 6.009

4.  Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity.

Authors:  Adrian Elter; Desislava Yanakieva; David Fiebig; Kerstin Hallstein; Stefan Becker; Ulrich Betz; Harald Kolmar
Journal:  Front Immunol       Date:  2021-08-03       Impact factor: 7.561

5.  Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.

Authors:  Asim V Farooq; Simona Degli Esposti; Rakesh Popat; Praneetha Thulasi; Sagar Lonial; Ajay K Nooka; Andrzej Jakubowiak; Douglas Sborov; Brian E Zaugg; Ashraf Z Badros; Bennie H Jeng; Natalie S Callander; Joanna Opalinska; January Baron; Trisha Piontek; Julie Byrne; Ira Gupta; Kathryn Colby
Journal:  Ophthalmol Ther       Date:  2020-07-25

6.  Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.

Authors:  Jason J Zoeller; Aleksandr Vagodny; Veerle W Daniels; Krishan Taneja; Benjamin Y Tan; Yoko S DeRose; Maihi Fujita; Alana L Welm; Anthony Letai; Joel D Leverson; Vincent Blot; Roderick T Bronson; Deborah A Dillon; Joan S Brugge
Journal:  Breast Cancer Res       Date:  2020-11-30       Impact factor: 6.466

7.  Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics.

Authors:  Gail Lewis Phillips; Jun Guo; James R Kiefer; William Proctor; Daniela Bumbaca Yadav; Noel Dybdal; Ben-Quan Shen
Journal:  Breast Cancer Res Treat       Date:  2021-10-27       Impact factor: 4.872

8.  Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs).

Authors:  Ricarda M Hoffmann; Ben G T Coumbe; Debra H Josephs; Silvia Mele; Kristina M Ilieva; Anthony Cheung; Andrew N Tutt; James F Spicer; David E Thurston; Silvia Crescioli; Sophia N Karagiannis
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

Review 9.  How to select IgG subclasses in developing anti-tumor therapeutic antibodies.

Authors:  Jifeng Yu; Yongping Song; Wenzhi Tian
Journal:  J Hematol Oncol       Date:  2020-05-05       Impact factor: 17.388

10.  Binding and functional profiling of antibody mutants guides selection of optimal candidates as antibody drug conjugates.

Authors:  John C Zwaagstra; Traian Sulea; Jason Baardsnes; Stevo Radinovic; Yuneivy Cepero-Donates; Alma Robert; Maureen D O'Connor-McCourt; Ilia A Tikhomirov; Maria Luz Jaramillo
Journal:  PLoS One       Date:  2019-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.